^
    Back
    Association details:
    Biomarker:LIFR expression
    Cancer:Triple Negative Breast Cancer
    Drug:EC359 (LIF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 562: Novel combination therapy for treating TNBC using LIFR and HDAC Inhibitors

    Published date:
    05/15/2020
    Excerpt:
    Immunohistochemical analyses of breast tumors using tissue microarrays revealed significant expression of LIFR in TNBC tissues. Our results suggest that the combination therapy of HDACIs and EC359 provides therapeutic utility in overcoming the limitation of feedback activation of LIFR observed in the treatment of HDACIs in treating TNBC.
    Secondary therapy:
    histone deacetylase inhibitors/hypomethylating agents
    DOI:
    10.1158/1538-7445.AM2020-562